Share

Early-Life Exposure to Toxic Chemicals May Cause Behavioral, Psychological Problems

Early life exposure to a class of endocrine-disrupting chemicals (EDCs) called polychlorinated biphenyls (PCBs) may lead to behavioral problems in rats, according to a new animal study published in the Journal of the Endocrine Society. Endocrine-disrupting chemicals (EDCs) are chemicals that mimic, block or interfere with hormones in the body’s endocrine system and contribute to endocrine...
Share

Dr. Smith Goes to Washington

Lorenzo Smith takes his passion for science all the way to Capitol Hill PhD candidate Lorenzo Smith recently experienced his first Hill Day with the Endocrine Society’s advocacy team and discusses what the lawmakers shared with him about the importance of scientific research, as well as the heartfelt reason he first became interested in a...
Share

Pharma Fridays – December 6, 2024

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Amylyx Announces Pivotal Phase 3 GLP-1 Trial Design in Post-Bariatric Hypoglycemia On December 4, Amylyx announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, for the treatment of post-bariatric...
Share

Deciphering Science: Q&A with V. Krishna Chatterjee, MD

V-Chatterjee The Endocrine Society’s 2025 recipient of the Gerald D. Aurbach Award for Outstanding Translational Research, V. Krishna Chatterjee, MD, tells Endocrine News why it’s so important for clinicians and basic scientists to work together to improve human health. In 2021, when our lives were still gripped by the deadly COVID-19 pandemic, V. Krishna Chatterjee, MD,...
Share

2024 Marked Year of Significant Accomplishments at the Society

John_Newell-Price It has been a remarkable year for the Endocrine Society! As the year draws to a close it’s timely to reflect on what we achieved over the past 12 months. Over this year we launched two new meetings, merged with an endocrine program directors’ association, entered partnerships to enhance our educational offerings, and created a...
Share

Pharma Fridays – November 29, 2024

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Exelixis, Inc. on November 26 announced that the U.S. Food and Drug Administration (FDA) has notified the company...